Management of Hypersensitivity Reaction to Polymethyl-Methacrylate Bone Cement
Treat acute hypersensitivity reactions to PMMA bone cement using standard anaphylaxis management protocols, with epinephrine as first-line therapy for severe reactions, and remove the cement implant if delayed-type hypersensitivity is confirmed. 1
Acute Intraoperative Management
Immediate Recognition and Treatment
When hypersensitivity occurs during cement insertion, manage it identically to any anaphylactic reaction occurring during anesthesia. 1 The key distinction is that PMMA reactions typically present as hypotension and cardiovascular collapse rather than through an IgE-mediated mechanism, though the clinical management remains the same. 1
Administer epinephrine immediately if the patient develops:
- Cardiovascular collapse or hypotension (systolic BP drop >30% from baseline) 1
- Bronchospasm or airway obstruction 1
- Diffuse urticaria with respiratory or cardiovascular involvement 1, 2
Supportive measures include:
- Aggressive fluid resuscitation with crystalloids to maintain systolic blood pressure within 20% of pre-induction values 1
- Vasopressors (metaraminol or additional epinephrine) for refractory hypotension 1
- Antihistamines (diphenhydramine 50 mg IV) for cutaneous manifestations 1, 2
- Corticosteroids (hydrocortisone 200 mg IV) for persistent symptoms 1
Critical Intraoperative Considerations
The reaction typically occurs during or immediately after cement insertion, not from skin contact with the material. 1 Methylmethacrylate has been associated with hypotension and systemic reactions through non-immunologic mechanisms (direct mast cell activation or free monomer effects), though no IgE mechanism has been documented in most cases. 1
Maintain invasive blood pressure monitoring for high-risk patients (elderly, male sex, significant cardiopulmonary disease, or diuretic use) throughout cement insertion and prosthesis placement. 1
Post-Reaction Evaluation and Diagnosis
Confirming the Diagnosis
Obtain patch testing to PMMA components if delayed-type hypersensitivity is suspected (symptoms developing hours to weeks after surgery, such as persistent erythema, eczema, wound breakdown, or implant loosening without infection). 3, 4, 5
Test for the following cement components:
- Polymethyl methacrylate (PMMA) monomer 3, 4
- Benzoyl peroxide 4
- N,N-dimethyl-p-toluidine 4
- Hydroquinone 4
- Antibiotics (particularly gentamicin if present in the cement) 4
Patch testing is the gold standard for diagnosing delayed-type hypersensitivity to bone cement, as demonstrated in the first reported case of PMMA cranioplasty hypersensitivity where diagnosis was confirmed 42 days post-operatively. 3
Ruling Out Alternative Diagnoses
Exclude infection and mechanical failure first before attributing symptoms to cement allergy, as these are far more common causes of implant complications. 4, 5 The prevalence of true PMMA allergy ranges from only 0.6% to 1.6%. 3
Definitive Management of Confirmed Hypersensitivity
Surgical Intervention
Remove the cemented implant and replace with a cementless prosthesis if patch testing confirms PMMA hypersensitivity and the patient has persistent symptoms (pain, loosening, fistula formation, or pseudotumor). 4, 5, 6, 7
Document the specific cement brand and components used in the electronic health record to guide future surgical planning. 1, 8
Long-Term Outcomes
Pseudotumor formation can occur as a rare complication of chronic PMMA hypersensitivity, developing over years (one case reported 13 years post-operatively). 6 This represents a severe inflammatory response requiring implant removal and revision to cementless fixation. 6
Prevention Strategies for Future Procedures
Preoperative Screening
No validated preoperative screening test exists to predict PMMA hypersensitivity before first exposure. 3, 5 However, obtain a detailed occupational and allergy history focusing on:
- Occupational exposure to acrylates (nail technicians, dental workers, orthopedic personnel) 4, 7
- Prior reactions to dental acrylics or artificial nails 5, 7
- History of contact dermatitis to adhesives or plastics 4, 5
If the patient reports prior acrylate exposure with dermatitis, perform preoperative patch testing to PMMA and related compounds before proceeding with cemented arthroplasty. 5, 7
Intraoperative Risk Reduction
For patients at higher risk of cardiovascular events during cemented arthroplasty:
- Use pressurized lavage to clean the femoral canal of fat and marrow 1
- Insert cement retrograde with a distal suction catheter 1
- Avoid excessive manual pressurization in elderly patients or those with cardiopulmonary disease 1
- Ensure adequate hydration before and during cement insertion 1
- Have vasopressors drawn and ready at the time of cementation 1
Communicate verbally with the anesthesia team immediately before instrumenting the femoral canal and inserting cement, as this is the highest-risk period for cardiovascular collapse. 1
Common Pitfalls to Avoid
Do not confuse immediate cardiovascular reactions with true IgE-mediated allergy. Most PMMA reactions during surgery are due to free monomer, fat emboli, or direct mast cell activation rather than specific IgE antibodies. 1 This distinction does not change acute management but affects long-term planning.
Do not assume all post-operative complications are allergic. Infection and mechanical loosening are far more common than cement hypersensitivity (which occurs in <2% of patients). 3, 4 Always rule out infection before attributing symptoms to allergy. 4, 5
Do not dismiss delayed symptoms (appearing weeks to months post-operatively) as unrelated to the cement. Delayed-type hypersensitivity can present with an extremely delayed onset, as documented up to 42 days after cranioplasty. 3
Healthcare workers with repeated cement exposure can develop hand eczema or occupational asthma from acrylate monomers. 4 This represents a separate occupational health concern requiring appropriate protective equipment and ventilation.